Prediction of incident heart failure by serum amino‐terminal pro‐B‐type natriuretic peptide level in a community‐based cohort

Campbell, Duncan J.; Gong, Fei; Jelinek, Michael; Castro, J.M.; Coller, J.; McGrady, Michele; Boffa, Umberto; Shiel, Louise; Wang, Bing Hui; Liew, Danny; Wolfe, Rory; Stewart, Simon; Owen, Alice; Krum, Henry; Reid, Christopher M.; Prior, David

doi:10.1002/ejhf.1381

Cited by 23 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study has been described elsewhere, [11][12][13] and participant recruitment and baseline assessment are described in the Supporting Information. The study has been described elsewhere, [11][12][13] and participant recruitment and baseline assessment are described in the Supporting Information.…”

Section: Study Populationmentioning

confidence: 99%

“…The SCReening Evaluation of the Evolution of New Heart Failure (SCREEN-HF) study was a community-based evaluation of the use of serum amino-terminal pro-B-type natriuretic peptide to identify individuals with cardiac dysfunction (as assessed by echocardiography) and increased risk of HF and other CVD events. The study has been described elsewhere, [11][12][13] and participant recruitment and baseline assessment are described in the Supporting Information. A flow chart for participant recruitment and follow-up is shown in Supporting Information, Figure S1.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Age‐specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure

et al. 2019

Self Cite

View full text Add to dashboard Cite

Aims We investigated whether addition of diastolic dysfunction (DD) and longitudinal strain (LS) to Stage B heart failure (SBHF) criteria (structural or systolic abnormality) improves prediction of symptomatic HF in participants of the SCReening Evaluation of the Evolution of New Heart Failure study, a self‐selected population at increased cardiovascular disease risk recruited from members of a health insurance fund in Melbourne and Shepparton, Australia. Both American Society of Echocardiography and European Association of Cardiovascular Imaging (ASE/EACVI) criteria and age‐specific Atherosclerosis Risk in Communities (ARIC) study criteria, for SBHF and DD, and ARIC criteria for abnormal LS, were examined. Methods and results Inclusion criteria were age ≥60 years with one or more of self‐reported ischaemic or other heart disease, irregular or rapid heart rhythm, cerebrovascular disease, renal impairment, or treatment for hypertension or diabetes for ≥2 years. Exclusion criteria were known HF, or ejection fraction <50% or >mild valve abnormality detected on previous echocardiography or other imaging. Echocardiography was performed in 3190 participants who were followed for a median of 3.9 (interquartile range: 3.4, 4.5) years after echocardiography. Symptomatic HF was diagnosed in 139 participants at a median of 3.1 (interquartile range: 2.1, 3.9) years after echocardiography. ARIC structural, systolic, and diastolic abnormalities predicted HF in univariate and multivariable proportional hazards analyses, whereas ASE/EACVI structural and systolic, but not diastolic, abnormalities predicted HF. ARIC and ASE/EACVI SBHF criteria predicted HF with sensitivities of 81% and 55%, specificities of 39% and 76%, and C statistics of 0.60 (95% confidence interval: 0.57, 0.64) and 0.66 (0.61, 0.71), respectively. Adding ARIC DD to SBHF increased sensitivity to 94% with specificity of 24% and C statistic of 0.59 (0.57, 0.61), whereas addition of ASE/EACVI DD to SBHF increased sensitivity to 97% but reduced specificity to 9% and the C statistic to 0.52 (0.50, 0.54, P < 0.0001). Addition of LS to ARIC or ASE/EACVI SBHF criteria had minimal impact on prediction of HF. Conclusions Age‐specific ARIC DD criteria, but not ASE/EACVI DD criteria, predicted symptomatic HF, and addition of age‐specific ARIC DD criteria to ARIC SBHF criteria improved prediction of symptomatic HF in asymptomatic individuals with cardiovascular disease risk factors. Addition of LS to ASE/EACVI or ARIC SBHF criteria did not improve prediction of symptomatic HF.

show abstract

Section: Study Populationmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

Age‐specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…NT-proBNP cut-points of 11,16, and 25 pmol/L for individuals aged 60-69, 70-79, and ≥ 80 years, respectively, achieved sensitivities > 75% and specificities of 47-69% for 5-year prediction of total HF in men and women in all age subgroups. 3 Klotho, an essential co-receptor for fibroblast growth factor (FGF)-23, has potentially beneficial inhibitory effects on the renin-angiotensin system. Bergmark et al 4 evaluated the prognostic value of Klotho and FGF-23 levels in the prediction of cardiovascular death or HF hospitalization in 3555 patients with stable ischaemic heart disease and left ventricular ejection fraction (LVEF) > 40% enrolled in the Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) trial of trandolapril vs. placebo.…”

Section: Biomarkers and Prediction Of Heart Failure Developmentmentioning

confidence: 99%

April 2019 at a glance: prediction of heart failure, left atrial function, cardio‐oncology

Metra

2019

European J of Heart Fail

View full text Add to dashboard Cite

“…[13][14][15][16] In addition to aiding in the diagnosis of HF, NT-proBNP also improves risk prediction for CVD outcomes as well as mortality. [17][18][19][20][21][22][23][24][25][26][27][28][29][30]…”

Section: Introductionmentioning

confidence: 99%

Elevated N‐terminal prohormone of brain natriuretic peptide among persons living with HIV in a South African peri‐urban township

et al. 2020

View full text Add to dashboard Cite

Aims Efforts to improve access to antiretroviral therapy (ART) have shifted morbidity and mortality among persons living with HIV (PLWH) from AIDS to non-communicable diseases, such as cardiovascular disease (CVD). However, contemporary data on CVD among PLWH in sub-Saharan Africa in the current ART era are lacking. The aim of this study was to assess the burden of cardiac stress among PLWH in South Africa via measurement of N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Methods and results NT-proBNP was measured at baseline in 224 PLWH enrolled in a sub-study of a tuberculosis vaccine trial in Khayelitsha township near Cape Town, South Africa. Thresholds were applied at the assay's limit of detection (≥137 pg/mL) and a level indicative of symptomatic heart failure in the acute setting (>300 pg/mL). Mean (SD) age of participants was 39 (6) years, 86% were female, and 19% were hypertensive. Mean (SD) duration of HIV diagnosis was 8.3 (3.9) years and CD4 + count was 673 (267) with 79% prescribed ART for a duration of 5.6 (2.7) years. Thirty-one percent of participants had NT-proBNP > 300 pg/mL. Elevated vs. undetectable NT-proBNP level was associated with older age (P = 0.04), no ART (P = 0.03), and higher plasma tumour necrosis factor-α (P = 0.01). Conclusions Among South African PLWH largely free of known CVD and on ART with high CD4 + counts and few comorbidities, we observed a high proportion with elevated NT-proBNP levels, suggesting the burden of cardiac stress in this population may be high. This observation underscores the need for more in-depth research, including the current effect of HIV on heart failure risk among a growing ART-treated population in sub-Saharan Africa.

show abstract

Prediction of incident heart failure by serum amino‐terminal pro‐B‐type natriuretic peptide level in a community‐based cohort

Cited by 23 publications

References 30 publications

Age‐specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure

Age‐specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure

April 2019 at a glance: prediction of heart failure, left atrial function, cardio‐oncology

Elevated N‐terminal prohormone of brain natriuretic peptide among persons living with HIV in a South African peri‐urban township

Contact Info

Product

Resources

About